The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage

Search this Article

Author(s)

    • UEYAMA SEIICHI
    • Pharmacology, Lead Optimization, Drug Innovation and Approval Division, Aventis Pharma Ltd.
    • ARAI YOSHINORI
    • Pharmacology, Lead Optimization, Drug Innovation and Approval Division, Aventis Pharma Ltd.
    • YOSHIDA YASUSHI
    • Pharmacology, Lead Optimization, Drug Innovation and Approval Division, Aventis Pharma Ltd.
    • KANEDA TOSHIO
    • Department of Oral Anatomy, Meikai University School of Dentistry
    • SATO TAKUYA
    • Department of Oral Anatomy, Meikai University School of Dentistry
    • SHIN KITETSU
    • Department of Periodontology, Meikai University School of Dentistry

Journal

  • J Bone Miner Metab.

    J Bone Miner Metab. 22(4), 318-328, 2004-05-30

References:  69

Cited by:  2

Codes

  • NII Article ID (NAID)
    10013606023
  • NII NACSIS-CAT ID (NCID)
    AA10747551
  • Text Lang
    ENG
  • Article Type
    Journal Article
  • ISSN
    09148779
  • Data Source
    CJP  CJPref 
Page Top